BeiGene (Suzhou) Co., Ltd.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$635,193
Doctors Paid
16
Transactions
197
2023 Total
$17,843
Payment Breakdown by Category
Research$408,000 (64.2%)
Consulting$227,193 (35.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $408,000 | 188 | 64.2% |
| Consulting Fee | $227,193 | 9 | 35.8% |
Payments by Type
Research
$408,000
188 transactions
General
$227,193
9 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A Randomized, Placebo-Controlled, Double-Blind Phase 3 Study to Evaluate the Efficacy and Safety of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First-Line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma | $121,115 | 0 | 44 |
| A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate Safety and Efficacy of BGB-3111, a Bruton's Tyrosine Kinase (BTK) Inhibitor in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) | $74,865 | 5 | 25 |
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Patients With Localized Esophageal Squamous Cell Carcinoma | $61,895 | 0 | 19 |
| A Single-Arm, Multi-Center, Open-Label, Phase 2 Study to Evaluate Efficacy and Safety of Tislelizumab (BGB-A317), an Anti-PD-1 Monoclonal Antibody, as Monotherapy in Patients With Previously-Treated Locally Advanced Unresectable or Metastatic Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Solid Tumors | $56,520 | 0 | 31 |
| Phase 3, Double-Blind, Randomized Study to Compare the Efficacy and Safety of Tislelizumab Combined With Chemotherapy Versus Chemotherapy as First-Line Treatment for Recurrent or Metastatic Nasopharyngeal Cancer | $28,055 | 0 | 21 |
| A Phase 2, Single-Arm, Open-Label, Multicenter Study of Bruton's Tyrosine Kinase (BTK) Inhibitor BGB-3111 in Chinese Subjects With Relapsed/Refractory Waldenstrom's Macroglobulinemia (WM) | $20,775 | 3 | 7 |
| An Open Label, Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of BGB-290 in the Treatment of Metastatic HER2-Negative Breast Cancer Patients With BRCA Mutation in China | $19,480 | 1 | 17 |
| An Open Label, Multi-Center Phase I/II Study to Evaluate Efficacy and Safety of BGB-290 in Chinese Subjects With Advanced Ovarian Cancer, Fallopian Cancer, and Primary Peritoneal Cancer or Advanced Triple Negative Breast Cancer | $10,060 | 3 | 9 |
| A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Compare the Efficacy and Safety of Neoadjuvant Treatment With Tislelizumab (BGB-A317, Anti-PD-1 Antibody) or Placebo Plus Platinum-Based Doublet Chemotherapy Followed By Adjuvant Tislelizumab or Placebo in Resectable Stage II or IIIA Non-Small Cell Lung Cancer | $8,910 | 0 | 1 |
| A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate Efficacy and Safety of BGB-3111, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Subjects With Refractory or Relapsed Mantle Cell Lymphoma (MCL) | $3,430 | 2 | 9 |
| A Phase 3, Randomized, Blinded, Placebo-controlled Study Of Tislelizumab (bgb-a317) Plus Chemoradiotherapy Followed By Tislelizumab Monotherapy In Newly Diagnosed, Stage Iii Subjects With Locally Advanced, Unresectable Non-small Cell Lung Cancer | $2,895 | 0 | 5 |
Payments by Medical Specialty
| Specialty | Total Paid | Doctors | Avg/Doctor |
|---|---|---|---|
| Hematology & Oncology | $245,735 | 7 | $35,105 |
| Hematology | $21,263 | 3 | $7,088 |
| Diagnostic Radiology | $15,380 | 4 | $3,845 |
| Specialist | $6,500 | 1 | $6,500 |
| Dermatology | $2,850 | 1 | $2,850 |
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2022 |
|---|---|---|---|---|
| Dr. Arjun Iyengar, M.d, M.D | Hematology & Oncology | New York, NY | $200,000 | $0 |
| Mark Litzow, M.d, M.D | Hematology & Oncology | Rochester, MN | $16,575 | $0 |
| Jacalyn Rosenblatt, M.d, M.D | Hematology | Boston, MA | $13,625 | $0 |
| Dr. Stephanie Bernstein, Md, MD | Hematology & Oncology | Winchester, MA | $8,445 | $0 |
| Anthony Letai, Md, MD | Hematology & Oncology | Boston, MA | $8,345 | $0 |
| Dr. Eric Jacobsen, Md, MD | Hematology & Oncology | Boston, MA | $7,605 | $0 |
| Dr. Steven Treon, Md, Phd, MD, PHD | Specialist | Boston, MA | $6,500 | $0 |
| Dr. Joseph Mikhael, M.d, M.D | Hematology | Scottsdale, AZ | $6,370 | $0 |
| Dr. Shital Makim, Md, MD | Diagnostic Radiology | Boston, MA | $5,320 | $0 |
| Sherelle Laifer-Narin, Md, MD | Diagnostic Radiology | New York, NY | $4,000 | $0 |
| Matthew Barish, M.d, M.D | Diagnostic Radiology | Manhasset, NY | $3,680 | $0 |
| David Avigan, M.d, M.D | Hematology & Oncology | Boston, MA | $3,150 | $0 |
| Dr. Nikolai Klebanov, Md, MD | Dermatology | Beverly, MA | $2,850 | $0 |
| Prof. Vassilios Raptopoulos, M.d, M.D | Diagnostic Radiology | Boston, MA | $2,380 | $0 |
| Jeffrey Zwicker, M.d, M.D | Hematology & Oncology | New York, NY | $1,615 | $0 |
| Dr. Delong Liu, M.d., Ph.d, M.D., PH.D | Hematology | Hawthorne, NY | $1,268 | $0 |
About BeiGene (Suzhou) Co., Ltd.
BeiGene (Suzhou) Co., Ltd. has made $635,193 in payments to 16 healthcare providers, recorded across 197 transactions in the CMS Open Payments database. In 2023, the company paid $17,843. The top product by payment volume is BRUKINSA ($288,913).
Payments were distributed across 5 medical specialties. The top specialty by payment amount is Hematology & Oncology ($245,735 to 7 doctors).
Payment categories include: Consulting ($227,193), Research ($408,000).